Results 251 to 260 of about 249,915 (344)

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

open access: yesCancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai   +6 more
wiley   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

open access: yesCancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng   +32 more
wiley   +1 more source

Novel Transthoracic Pulmonary Valve Implantation Using Self‐Expanding Salus Valve: A Prospective Study of Safety and Mid‐Term Outcomes

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter pulmonary valve replacement (TPVR) has emerged as a valuable treatment for severe pulmonary regurgitation (PR). The Salus valve (Balance Medical Technology Co. Ltd., Beijing, China) represents a novel self‐expanding valve stent designed for deployment through a transthoracic approach with a small subxiphoid incision ...
Ziqin Zhou   +6 more
wiley   +1 more source

The International TrifectaTM and EpicTM Valve‐in‐Valve Registry: Insights Into Clinical & Hemodynamic Outcomes

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Little is known about the clinical and hemodynamic outcome of valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR) for failed Trifecta surgical aortic bioprotheses. Aims We aimed to compare outcomes of valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR into failed TrifectaTM vs.
Matthias Raschpichler   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy